Alterity Therapeutics (ASX:ATH) Loans Receivable: A$0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ATH Alterity Therapeutics Ltd ASX:ATH
31 GF Score
Price A$0.45
! 1 Warning Sign
View Full Analysis

What is Alterity Therapeutics Loans Receivable?

Alterity Therapeutics ASX:ATH -2.17% 31 Loans Receivable is A$0.00 Mil as of Jun. 2026. GuruFocus rates ASX:ATH with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

Alterity Therapeutics's Loans Receivable for the quarter that ended in Jun. 2026 was A$0.00 Mil.

Alterity Therapeutics Loans Receivable Related Terms

Alterity Therapeutics Loans Receivable Historical Data

* Premium members only.

The historical data trend for Alterity Therapeutics's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterity Therapeutics Loans Receivable Chart

Alterity Therapeutics Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Alterity Therapeutics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:ATH
31GF Score
Alterity Therapeutics Ltd ASX:ATH
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alterity Therapeutics Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of A$0.00 Mil mean?
Alterity Therapeutics (ASX:ATH) has a Loans Receivable of A$0.00 Mil as of Jun. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Alterity Therapeutics and its competitors.
Is Alterity Therapeutics' Loans Receivable too high?
Alterity Therapeutics' current Loans Receivable is A$0.00 Mil. Overall, Alterity Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Alterity Therapeutics' Loans Receivable compare to VRTX and REGN?
Alterity Therapeutics' Loans Receivable of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Biotechnology company?
A good Loans Receivable depends on the Biotechnology industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Alterity Therapeutics and its competitors. Alterity Therapeutics's current Loans Receivable is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alterity Therapeutics stock overvalued right now?
Alterity Therapeutics (ASX:ATH) has a current Loans Receivable of A$0.00 Mil. The current Loans Receivable is A$0.00 Mil. Alterity Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Alterity Therapeutics (ASX:ATH), the current Loans Receivable is A$0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alterity Therapeutics Business Description

Other Exchanges ATHE:USAPBN:Germany
Address 350 Collins Street, Suite 4, Level 14, Melbourne, VIC, AUS, 3000
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
31GF Score

Get the complete analysis for ASX:ATH

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.45
Price